获得血友病A的创新疗法
Massimo Franchini1, Daniele Focosi2
1Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantua, Italy.
Seminars in thrombosis and hemostasis
|February 23, 2024
概括
获得性血友病A (AHA) 是一种罕见的出血疾病,由自身抗体引起. 本综述检查了艾米齐祖马布和利图西马布作为管理AHA及其抑制剂的有希望的非标签疗法.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 自免疫性疾病 自免疫性疾病
背景情况:
- 获得性血友病A (AHA) 是一种罕见的,可能危及生命的自身免疫性出血障碍.
- 它是由针对凝血因子VIII的自身抗体引起的,在大约一半的病例中具有特异性发作.
- 触发因素包括自身免疫性疾病,癌症,药物,感染或怀孕.
研究的目的:
- 审查埃米齐祖马布和利图西马布在治疗获得的血友病A.目前的临床使用情况.
- 评估这些药物作为AHA的创新,非标签治疗选择.
主要方法:
- 这是一个对现有文学作品的叙述性回顾.
- 重点是埃米齐祖马布和利图西马布在AHA患者的临床应用.
- 该综述综合了血液静止和免疫抑制策略的数据.
主要成果:
- 埃米齐祖马布和利图西马布正在作为AHA的新疗法进行研究.
- 这些药物代表了有希望的非标签治疗选择.
- 目前的研究重点是它们在治疗出血和消除抑制剂方面的有效性.
结论:
- 艾米齐祖马布和利图西马布显示出作为获得性血友病A的有价值治疗剂的潜力.
- 需要进一步的研究来确定最佳的使用和有效性.
- 这些药物为患有这种罕见的出血障碍的患者提供了新的希望.
更多相关视频
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
697
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
697
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
181
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
181
Extrinsic and Intrinsic Pathways of Hemostasis
7.6K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.6K
Introduction to Hemostasis
7.7K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
7.7K
Disorders of Hemostasis
906
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
906
Gene Therapy
25.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.4K


